KarXT Phase 3 (NCT06585787): Muscarinic Agonist for Alzheimer's Disease Agitation
Overview
flowchart TD
clinical_trials_karxt_nct06585["KarXT Phase 3 AD Agitation NCT06585787"]
clinical_trials_karxt_nct06585["Phase"]
clinical_trials_karxt_nct06585 -->|"related to"| clinical_trials_karxt_nct06585
style clinical_trials_karxt_nct06585 fill:#81c784,stroke:#333,color:#000
clinical_trials_karxt_nct06585["Muscarinic"]
clinical_trials_karxt_nct06585 -->|"related to"| clinical_trials_karxt_nct06585
style clinical_trials_karxt_nct06585 fill:#81c784,stroke:#333,color:#000
clinical_trials_karxt_nct06585["Agonist"]
clinical_trials_karxt_nct06585 -->|"related to"| clinical_trials_karxt_nct06585
style clinical_trials_karxt_nct06585 fill:#81c784,stroke:#333,color:#000
clinical_trials_karxt_nct06585["Alzheimer"]
clinical_trials_karxt_nct06585 -->|"related to"| clinical_trials_karxt_nct06585
style clinical_trials_karxt_nct06585 fill:#81c784,stroke:#333,color:#000
style clinical_trials_karxt_nct06585 fill:#4fc3f7,stroke:#333,color:#000
KarXT (xanomeline/trospium) is a novel muscarinic acetylcholine receptor agonist being developed by Bristol-Myers Squibb for the treatment of agitation in Alzheimer's disease (AD). This Phase 3 trial (NCT06585787) is currently recruiting participants to evaluate the efficacy and safety of KarXT in AD patients with clinically significant agitation["@clinicaltrialsgov"].
...KarXT Phase 3 (NCT06585787): Muscarinic Agonist for Alzheimer's Disease Agitation
Overview
Mermaid diagram (expand to render)
KarXT (xanomeline/trospium) is a novel muscarinic acetylcholine receptor agonist being developed by Bristol-Myers Squibb for the treatment of agitation in Alzheimer's disease (AD). This Phase 3 trial (NCT06585787) is currently recruiting participants to evaluate the efficacy and safety of KarXT in AD patients with clinically significant agitation["@clinicaltrialsgov"].
Agitation represents one of the most challenging neuropsychiatric symptoms in Alzheimer's disease, affecting up to 70% of patients during the disease course. It includes behaviors such as aggression, restlessness, pacing, and resistiveness to care, significantly impacting quality of life for both patients and caregivers["@agitation2023"].
| Attribute | Details |
|-----------|---------|
| NCT Number | NCT06585787 |
| Sponsor | Bristol-Myers Squibb |
| Drug | KarXT (xanomeline/trospium) |
| Phase | Phase 3 |
| Indication | Agitation in Alzheimer's Disease |
| Status | Recruiting |
| Participants | 406 |
| Study Start | 2024 |
| Estimated Completion | 2026-2027 |
Mechanism of Action
Dual Muscarinic Agonism
KarXT is a fixed-dose combination of two compounds:
Xanomeline: A selective M1 and M4 muscarinic acetylcholine receptor agonist that crosses the blood-brain barrier
Trospium Chloride: A quaternary ammonium muscarinic antagonist that does not cross the blood-brain barrierThis unique co-formulation allows xanomeline to activate central M1 and M4 receptors while trospium blocks peripheral muscarinic receptors, preventing unwanted side effects such as dry mouth, constipation, and urinary retention[@xanomeline2023].
Receptor Pharmacology
| Receptor | Location | Effect | Therapeutic Implication |
|----------|----------|--------|------------------------|
| M1 | Central | Cognitive enhancement | Memory and learning improvement |
| M4 | Central | Anti-agitation | Reduction of neuropsychiatric symptoms |
| M2/M3 | Peripheral | Autonomic effects | Blocked by trospium |
The selective activation of M1 (cognitive) and M4 (anti-agitation) receptors provides a novel approach that differs from current antipsychotic treatments, which primarily target dopamine and serotonin receptors.
Why Muscarinic Agonism for AD Agitation
The cholinergic system is severely compromised in Alzheimer's disease:
- Basal forebrain cholinergic neurons degenerate early in AD
- Cholinergic innervation of cortex and hippocampus diminishes
- This loss correlates with both cognitive decline and behavioral symptoms
By activating M1/M4 receptors, KarXT aims to:
Improve cognitive function through M1 receptor signaling
Reduce agitation and psychosis through M4 receptor signaling
Provide a non-dopaminergic approach avoiding antipsychotic side effectsClinical Development
Phase 2 Results (EMERALD)
Prior Phase 2 trials demonstrated promising results:
- Significant reduction in agitation symptoms (Cohen-Mansfield Agitation Inventory)
- Cognitive preservation with no worsening compared to placebo
- Manageable safety profile with primarily mild-to-moderate cholinergic effects
Phase 3 Program
The Phase 3 program includes multiple trials (including NCT06585787):
- Primary endpoint: Change in Cohen-Mansfield Agitation Inventory (CMAI) score
- Key secondary endpoints: CGI-I, Neuropsychiatric Inventory (NPI), ADCS-ADL
- Duration: 12-week treatment period
- Population: Moderate-to-severe agitation in Alzheimer's disease
Agitation in Alzheimer's Disease
Clinical Significance
Agitation in AD manifests as:
- Physical aggression (hitting, kicking, pushing)
- Verbal aggression (screaming, cursing)
- Restlessness and pacing
- Resistiveness to care
- Disinhibition
This symptom significantly increases caregiver burden and is a leading cause of nursing home placement.
Current Treatment Limitations
| Treatment | Mechanism | Limitations |
|-----------|-----------|-------------|
| Risperidone | D2 antagonist | Extrapyramidal symptoms, stroke risk |
| Quetiapine | Multi-receptor | Sedation, metabolic effects |
| Aripiprazole | Partial D2 agonist | Limited efficacy |
| Benzodiazepines | GABA agonist | Sedation, fall risk, cognitive worsening |
KarXT represents a novel mechanism targeting the cholinergic deficit directly, potentially avoiding these limitations.
Bristol-Myers Squibb Acquisition
BMS acquired Karuna Therapeutics (the original developer of KarXT) in 2023 for approximately $14 billion — representing the largest CNS acquisition in BMS history. This acquisition underscores BMS's strategic commitment to neuropsychiatry and their belief in KarXT's commercial potential.
The AD agitation indication represents a significant market opportunity:
- ~40% of AD patients experience clinically significant agitation
- Estimated annual market: $10+ billion
- First novel mechanism in decades for this indication
Safety and Tolerability
Common Adverse Events
- Dry mouth
- Constipation
- Urinary retention
- Nausea
- Dizziness
Advantages Over Current Treatments
No black box warning: Not an antipsychotic, no increased mortality risk
Cognitive benefit: M1 activation may improve cognition
Non-dopaminergic: Avoids extrapyramidal symptoms
Non-sedating: Does not cause significant drowsinessRegulatory Status
- Fast Track Designation: Granted by FDA for AD agitation
- Priority Review: Potential if Phase 3 trials positive
- Expected FDA Decision: 2026-2027 (if successful)
Cross-Links to NeuroWiki
- [Alzheimer's Disease](/diseases/alzheimers-disease) — Target indication
- [Agitation in Alzheimer's Disease](/therapeutics/agitation-alzheimers) — Related condition
- [Cholinergic System](/mechanisms/cholinergic-system) — Mechanism basis
- [Muscarinic Receptors](/entities/muscarinic-receptors) — Drug target
- [Bristol-Myers Squibb](/companies/bristol-myers-squibb) — Sponsor
References
Unknown, ClinicalTrials.gov. NCT06585787: KarXT for Agitation in Alzheimer's Disease (n.d.)
[Unknown, Agitation in Alzheimer's disease: prevalence and management. CNS Drugs. 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/37870923/)
[Unknown, Xanomeline: a novel muscarinic agonist for CNS disorders. J Pharmacol Exp Ther. 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/37205258/)
Unknown, BMS to acquire Karuna Therapeutics for $14 billion. Press Release. 2023 (2023)